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The brain regulates physiological functions integral to survival. However, the insight
into brain neuronal regulation of peripheral immune function and the neuromediator
systems and pathways involved remains limited. Here, utilizing selective genetic and
pharmacological approaches, we studied the role of forebrain cholinergic signaling
in the regulation of peripheral immune function and inflammation. Forebrain-selective
genetic ablation of acetylcholine release and vagotomy abolished the suppression of
serum TNF by the centrally-acting cholinergic drug galantamine in murine endotoxemia.
Selective stimulation of acetylcholine action on the M1 muscarinic acetylcholine
receptor (M1 mAChR) by central administration of the positive allosteric modulator
benzyl quinolone carboxylic acid (BQCA) suppressed serum TNF (TNFα) levels in
murine endotoxemia. This effect was recapitulated by peripheral administration of the
compound. BQCA also improved survival in murine endotoxemia and these effects
were abolished in M1 mAChR knockout (KO) mice. Selective optogenetic stimulation of
basal forebrain cholinergic neurons innervating brain regions with abundant M1 mAChR
localization reduced serum TNF in endotoxemic mice. These findings reveal that forebrain
cholinergic neurons regulate innate immune responses and inflammation, suggesting the
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possibility that in diseases associated with cholinergic dysfunction, including Alzheimer’s
disease this anti-inflammatory regulation can be impaired. These results also suggest
novel anti-inflammatory approaches based on targeting forebrain cholinergic signaling in
sepsis and other disorders characterized by immune dysregulation.
Keywords: forebrain cholinergic, cytokines, inflammation, vagus nerve, endotoxemia, sepsis, neural regulation
INTRODUCTION
The nervous system regulates and coordinates
physiological functions and defense mechanisms. A major
defense mechanism against pathogen invasion and tissue
injury is provided by the innate immune system through
inflammation (1). However, dysregulated immune responses and
aberrant inflammation are implicated in the etiology of sepsis,
inflammatory bowel disease, and many other life-threatening
and debilitating disorders (1–6). While accumulating evidence
reveals that the nervous system and specifically the vagus
nerve regulate immune function and inflammation, the role
of brain pathways in this context remains poorly understood
(2, 7, 8). The brain regulation of peripheral inflammation and
the mediating role of the vagus nerve have been indicated in
studies with the experimental anti-inflammatory compound
CNI-1493 (Semapimod). Administration of this molecule in the
brain suppresses serum TNF (TNF-α) in murine endotoxemia
and this effect is abrogated by surgical transection of the
vagus nerve (vagotomy) (9). CNI-1493 binds to muscarinic
acetylcholine receptors (mAChRs) (10) and administration of
compounds that mimic the action of acetylcholine on mAChRs
in the brain also suppresses circulating TNF and other pro-
inflammatory cytokines (10–12). In addition, galantamine, an
acetylcholinesterase inhibitor, which increases acetylcholine
levels suppresses peripheral pro-inflammatory cytokine levels
acting through a brain mAChR-mediated mechanism (13–
15). These cholinergic effects in the brain are linked with
activation of the vagus nerve-based inflammatory reflex
(11, 13, 14, 16, 17), a physiological immunoregulatory circuit
(18, 19) with recently demonstrated utility in treating human
inflammatory diseases (20, 21). These studies have implicated
brain cholinergic signaling in the regulation of pro-inflammatory
cytokine release and inflammation. The cholinergic system in
the brain has a diverse topographic neuronal organization and
projection patterns (22, 23), and specific insight into the role of
cholinergic pathways and receptors in the brain in peripheral
immunoregulation is presently lacking.
A major collection of cholinergic neurons is localized in the
basal forebrain (22, 24). These neurons project to forebrain
regions with abundant expression of M1 mAChRs, including
neocortical areas and the hippocampus (23), and regulate
neuroplasticity, cognition, and other processes (22, 23, 25).
Here, utilizing mice with selective genetic forebrain ablation of
acetylcholine release, positive allosteric M1 mAChR modulation,
and optogenetic stimulation of basal forebrain cholinergic
neurons, we indicate a role for forebrain cholinergic signaling via
M1 mAChRs in the physiological regulation of inflammation.
RESULTS
Acetylcholine in Forebrain Mediates
Cholinergic Suppression of Peripheral
Pro-inflammatory Cytokine Release via a
Vagus Nerve-Dependent Signaling
To investigate the role of forebrain neuronal acetylcholine
in regulating peripheral inflammation, we utilized mice
with selective forebrain deprivation of acetylcholine release
and galantamine, a centrally-acting cholinergic drug (an
acetylcholinesterase inhibitor) with anti-inflammatory properties
(13, 14). A major molecular determinant of acetylcholine release
is the vesicular acetylcholine transporter (VAChT), which loads
acetylcholine in vesicles prior to its release in the synaptic
cleft (26, 27). We used mice with Cre-loxP-based forebrain
VAChT ablation, a genetic manipulation that provides a non-
invasive means of selective elimination of forebrain acetylcholine
release and cholinergic activity without loss of neurons (27).
This is important as cholinergic neurons can also secrete
GABA with ACh and targeting VAChT allows for selective
manipulation of ACh release (28–31). As shown in Figure 1A,
no VAChT immunoreactivity in the forebrain (hippocampus,
CA3 area shown) was detected in these VAChTNkx2.1−Cre−flox/flox
(VAChT−/−) mice as compared with VAChTflox/flox (VAChT+/+)
control mice. This observation was consistent with the previously
reported lack of VAChT immunoreactivity in several forebrain
areas of VAChT−/− mice and no significant alterations in
VAChT protein expression in brainstem regions as a result of
genetic deletion (27). The selective forebrain VAChT ablation
was not associated with differences in VAChT protein levels
(immunofluorescence) in the spinal cord and peripheral
neuronal varicosities in the heart (Figures 1B,C). These
observations indicated that VAChT ablation was limited to the
basal forebrain cholinergic system. Furthermore, no differences
were observed between VAChT−/− and VAChT+/+ mice on
24 h heart rate recording (Figure 1D). There were no differences
between the two groups of mice in heart rate responses to
atropine (mAChR blocker) and propranolol (beta adrenergic
receptor blocker) i.p. administrations (Figures 1E–G). In
addition, sensitivity to post-handling stress was similar between
genotypes, because heart rate responses to saline administration
did not differ between the two groups of mice (Figure S1).
The effects of acetylcholine in the brain can be modulated
(enhanced) through inhibiting its degradation using centrally-
acting acetylcholinesterase inhibitors, including galantamine.
Administration (i.p.) of galantamine in VAChT+/+ mice prior to
endotoxin significantly reduced serum TNF levels as compared
to vehicle administration (P = 0.017) (Figure 2A). However,
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FIGURE 1 | Morphological and functional evaluation of forebrain VAChT KO mice. (A) VAChT protein immunostaining (in green) shown in a hippocampal region of
VAChT+/+ mice is not detected in VAChT−/− mice (scale bar = 100µm). (B) VAChT protein immunostaining (in green) in spinal cord of VAChT+/+ and VAChT−/−
mice (scale bar = 20µm). (C) VAChT protein immunostaining (in green) in the heart right atrium of VAChT+/+ and VAChT−/− mice (scale bar = 20µm). (D) Freely
moving VAChTflox/flox (VAChT+/+) mice and VAChT Nkx2.1−Cre−flox/flox (VAChT−/−) mice exhibit no differences in heart rate during 24 h recording using
radio-frequency telemeters. Freely moving VAChT+/+ (open circles) and VAChT−/− mice (black circles) exhibit no difference in heart rate responses to atropine (E),
propranolol (F), or atropine and propranolol (G) i.p. administration (n = 4 mice/genotype).
galantamine failed to significantly alter serum TNF levels in
VAChT−/− mice (Figure 2A). In addition, serum TNF levels in
VAChT−/− mice were significantly higher than in VAChT+/+
mice during endotoxemia (P = 0.009) (Figure 2A), suggesting
that physiological cholinergic transmission in the forebrain
regulates peripheral innate immune responses. Galantamine
was previously shown to stimulate vagus nerve activity (17, 32).
We next examined the role of the vagus nerve in mediating
galantamine forebrain-triggered anti-inflammatory effect in
endotoxemic C57BL/6 mice. Galantamine administration
significantly decreased serum TNF levels as compared with
vehicle during endotoxemia in sham-operated (control) mice
(P = 0.019) (Figure 2B). This effect was markedly diminished
in mice with cervical unilateral vagotomy (Figure 2B), thus
indicating a role of the efferent vagus nerve. Collectively,
these data indicate that acetylcholine derived from cholinergic
neurons in forebrain plays a role in mediating the suppressive
effect of galantamine on peripheral TNF levels in a vagus
nerve-dependent manner during murine endotoxemia.
Stimulation of Acetylcholine Action on the
M1 mAChR by Allosteric Modulation
Suppresses Lethal Peripheral Inflammation
Basal forebrain cholinergic neurons project to regions with high
expression of M1 mAChR, including several neocortical areas
and the hippocampus. Acetylcholine released from these neurons
stimulates the postsynaptically locatedM1mAChR that processes
cholinergic transmission (33). Positive allosteric modulation of
the M1 mAChR is a selective approach of increasing endogenous
acetylcholine activity at the receptor (34, 35). To study the
effect of acetylcholine on brain M1 mAChR in the regulation of
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FIGURE 2 | Selective forebrain cholinergic deficit and vagotomy alter
cholinergic suppression of peripheral pro-inflammatory cytokine levels. (A)
Galantamine (Gal, i.p.) as compared to vehicle (Veh), suppresses serum TNF in
VAChT+/+ control mice, but not in VAChT−/− mice during endotoxemia, and
serum TNF in vehicle injected VAChT−/− mice are higher as compared to
VAChT+/+ control mice (*P = 0.017, **P = 0.007, two-way ANOVA, Sidak’s
multiple comparisons test), n = 6–7 per group. (B) Vagotomy (VgX) abolishes
the suppression of serum TNF in endotoxemic mice (*P = 0.019, two-way
ANOVA, Sidak’s multiple comparisons test), n = 6–8 per group. See Methods
for details.
peripheral inflammation, we used benzyl quinolone carboxylic
acid (BQCA), a positive allosteric modulator of M1 mAChR (34,
35). BQCA has previously been shown to selectively increase (up
to 129-fold) the functional affinity of endogenous acetylcholine
for M1 mAChR (35). Intracerebroventricular (i.c.v.) injection
of BQCA (5 µg/kg) resulted in significant suppression of
serum TNF as compared with vehicle administration following
endotoxin challenge (P = 0.018) (Figure 3A). This observation
indicated that selective activation of acetylcholine action on the
M1 mAChR in the brain suppresses peripheral inflammation
in murine endotoxemia. To facilitate subsequent studies with
BQCA, we examined whether peripheral administration of
BQCA, which is known to cross the blood brain barrier (34,
35), recapitulates anti-inflammatory effects. Intraperitoneal (i.p.)
treatment of mice with BQCA (1–20 mg/kg) resulted in a
dose-dependent decrease in serum TNF following endotoxin as
compared to vehicle injection (P < 0.001, when 20 mg/kg BQCA
was used) (Figure 3B). I.p. administration of BQCA also dose-
dependently improved the survival rate in this lethal murine
FIGURE 3 | Activation of acetylcholine action on the M1 mAChR using a
positive allosteric modulator (BQCA) suppresses serum TNF levels and
improves survival in endotoxemia. (A) BQCA (5 µ/kg, i.c.v.) suppresses serum
TNF (*P = 0.018, unpaired two-tailed Student’s t test), n = 6–7 per group. (B)
Peripheral i.p. administration of BQCA 1–20 (1–20 mg/kg) in endotoxemic
mice suppresses serum TNF levels (*P = 0.027, ***P = 0.0005, ****P <
0.0001, one-way ANOVA, Dunnett’s multiple comparisons test), n = 7–8 per
group. (C) Peripheral i.p. administration of BQCA 20 (20 mg/kg) in
endotoxemic mice improves survival in endotoxemia (*P = 0.035, Log-rank
test), n = 11–12 per group.
endotoxemia model as compared to vehicle administration (P =
0.035 when 20 mg/kg BQCA was used) (Figure 3C).
BQCA treatment (20 mg/kg, i.p.) did not significantly alter
serum TNF in M1 mAChR KO mice (as compared to vehicle
treatment), while in wild type (WT) mice this drug effect
was significant (P = 0.028) (Figure 4A). Previous studies have
shown that activation of brain mAChR-mediated cholinergic
signaling results in suppression of TNF in spleen, a major
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FIGURE 4 | Anti-inflammatory effects of BQCA in endotoxemia are mediated by M1 mAChRs. (A) Peripheral (i.p.) administration of BQCA (20 mg/kg, i.p.) suppresses
serum TNF in wild type (WT) mice and does not alter serum TNF in M1 mAChR KO mice during endotoxemia (*P = 0.01, two-way ANOVA, Sidak’s multiple
comparisons test), n = 8–10. (B) Peripheral (i.p.) administration of BQCA (20 mg/kg, i.p.) suppresses splenic TNF in WT mice and does not alter splenic TNF in M1
mAChR KO mice (*P = 0.017, two-way ANOVA, Sidak’s multiple comparisons test), n = 7–10. (C) Vagotomy (VgX) abolishes the effect of BQCA on splenic TNF
during endotoxemia (unpaired two-tailed Student’s t test), n = 7, 8. (D) Peripheral (i.p.) administration of BQCA (20 mg/kg, i.p.) improves survival in endotoxemic WT
mice and does not alter the survival rate in M1 mAChR KO mice during endotoxemia (*P = 0.028, Log-rank test), n = 15–18 per group. See Methods for details.
source of pro-inflammatory cytokines and an organ target of
the vagus-nerve-based inflammatory reflex (36–38). BQCA (i.p.)
administration 1 h prior to endotoxin significantly suppressed
splenic TNF in WT mice (P = 0.047) and did not alter splenic
TNF in M1 mAChR KO mice (Figure 4B). BQCA also failed to
significantly alter splenic TNF in endotoxemic WT mice with
unilateral cervical vagotomy (Figure 4C). In addition, BQCA
(20 mg/kg, i.p.) injected 1 h prior to endotoxin was sufficient to
significantly improve survival in WTmice (P= 0.028), but failed
to significantly alter survival in endotoxemic M1 mAChR KO
mice (Figure 4D). Together these results show that enhancement
of acetylcholine activity on the M1 mAChR is sufficient to
suppress inflammation in murine endotoxemia and that the
efferent vagus nerve is necessary for this anti-inflammatory effect.
Selective Optogenetic Stimulation of Basal
Forebrain Medial Septum Cholinergic
Neurons Suppresses Serum TNF Levels
We next examined whether the anti-inflammatory effect of
acetylcholine acting on M1 mAChR (achieved by allosteric
modulation with BQCA) could be replicated by direct
stimulation of basal forebrain cholinergic neurons in vivo.
The medial septum (medial septal nucleus) is a major nucleus
in the basal forebrain cholinergic system (22, 23). The medial
septum also plays an important role as a relay of afferent vagus
nerve signaling in the forebrain as recently demonstrated (39).
Accordingly, we stimulated basal forebrain medial septum
cholinergic neurons using a selective optogenetic approach
in transgenic mice. These mice express channelrhodopsin-2
coupled to a yellow fluorescent protein (ChR2-YFP) under
the control of the choline acetyltransferase (ChAT) promoter.
Immunofluorescent staining of brain slices confirmed the
neuronal colocalization of ChAT and ChR2-YFP in the medial
septum (Figure 5A) and the abundant expression of ChR2-YFP
in the medial septum and the adjacent vertical limb of the
diagonal band of Broca (Figure S2). Photoactivation of medial
septum neurons by laser light (473 nm) significantly suppressed
serum TNF levels compared with sham stimulation (P =
0.039) (Figure 5B) in mice with confirmed (by microscopic
histochemical evaluation) location of the fiber tip in the medial
septum (Figure S3; Supplementary Methods). Laser light
exposure of medial septum neurons in C57BL/6 mice not
expressing ChR2-YFP on cholinergic neurons (non-carriers)
was performed to control for possible confounding effects of
heat and other non-thermal effects of light. This manipulation
failed to alter serum TNF levels (Figure 5C) thus confirming
the specific cholinergic nature of the mechanism. As ChAT-
ChR2-YFP mice have been shown to overexpress VAChT (40, 41)
and present increased cholinergic tone, LPS was administered
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FIGURE 5 | Optogenetic stimulation of basal forebrain cholinergic neurons in the medial septum suppresses serum TNF in endotoxemic mice. (A) Immunostaining of
medial septum neurons in a brain section of a ChAT-ChR2-EYFP mouse: EYFP immunostaining (first and second panel); ChAT immunostaining of the same area (third
panel); and double immunostaining (fourth panel). (B) Optogenetic stimulation suppresses serum TNF during endotoxemia (*P = 0.039, unpaired two-tailed Student’s
t test), n = 5–6 per group. (C) Laser light exposure of medial septum neurons in control (non-carrier) mice does not significantly alter serum TNF levels during
endotoxemia (unpaired two-tailed Student’s t test), n = 6–7 per group. (D) LPS (i.p.) administration to ChAT-ChR2-EYFP (ChR2) and control (non-carrier, NC) mice
does not result in statistically different serum TNF levels, (unpaired two-tailed Student’s t test), n = 9 per group. See Methods for details.
to ChAT-ChR2-YFP and non-carrier mice not subjected to
anesthesia and surgical manipulation. No differences in serum
TNF levels upon LPS administration were observed between
the two groups of mice (Figure 5D), indicating that the genetic
modification by itself did not alter the inflammatory response.
These results show that selective activation of basal forebrain
medial septum cholinergic neurons decreases peripheral
inflammation in endotoxemia.
DISCUSSION
Here, we show a role for forebrain cholinergic signaling and the
M1 mAChR in the brain neuronal regulation of inflammation
through vagus nerve-mediated signaling.
Genetic ablation of VAChT, which eliminates synaptic
acetylcholine release from basal forebrain cholinergic neurons
(27), abolished the anti-inflammatory effect of the centrally-
acting acetylcholinesterase inhibitor galantamine. These findings
point to forebrain acetylcholine as a major mediator of
galantamine anti-inflammatory effects in endotoxemia. The
selective forebrain cholinergic deficit (in VAChT−/− mice) also
resulted in increased circulatory TNF levels in endotoxemicmice,
thus suggesting a tonic anti-inflammatory role of acetylcholine
in forebrain.
Forebrain areas, including the cortex (neocortex) and the
hippocampus have abundant (predominantly post-synaptic)
localizations of the M1 mAChR, which plays a major role
in processing the effects of acetylcholine released from basal
forebrain cholinergic neurons (22). Positive allostericmodulation
of the M1 mAChR by BQCA is a selective approach of
increasing the activity of the endogenous acetylcholine on
the receptor (34, 35). The anti-inflammatory effects of the
centrally-acting BQCA demonstrated here indicate a role of
acetylcholine acting on the M1 mAChR in controlling peripheral
inflammatory responses. Unilateral vagotomy attenuated the
anti-inflammatory effects of galantamine and BQCA, thus
indicating a brain-to periphery mediating role for the vagus
nerve. The vagus nerve is an important neuroanatomical
component of the inflammatory reflex (18) in which sensory and
motor vagus nerve signaling regulates cytokine production by
immune cells in the spleen, and alleviates inflammation (2, 19).
Importantly, recent studies demonstrated that afferent vagus
nerve signaling reaches the forebrain (hippocampus and cortex),
and identified basal forebrain cholinergic nuclei, including the
medial septum as major relay components (39, 42, 43). Together
with these findings, our observations suggest a role for the
medial septum in a forebrain regulatory hub of the inflammatory
reflex. This regulation possibly involves other brain regions
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throughmultisynaptic pathways with brainstem nuclei providing
peripheral vagus nerve projections. These brain networks remain
to be further elucidated.
In addition to positive allosteric modulation of acetylcholine
action on M1 mAChR, suppression of serum TNF levels
during endotoxemia was also achieved by selective optogenetic
stimulation of a subset of basal forebrain cholinergic neurons
in the medial septum. Although optogenetic stimulation was
performed in animals under isoflurane anesthesia and there
is some evidence that relatively high doses of isoflurane can
increase blood-brain barrier permeability (44), the proper sham
stimulation pointed to the specificity of the effect. Medial
septum cholinergic neurons innervate the hippocampus and the
parahippocampal region, which are interconnected with several
neocortical and subcortical areas (23, 24, 39). Multisynaptic
connections between the hippocampus and the hypothalamus
have also been described. Although we stereotactically targeted
optogenetic stimulation of the medial septum, a spread of
stimulation to adjacent cholinergic neurons in the diagonal band
of Broca cannot be excluded. Cholinergic neurons in the diagonal
band of Broca project to cortical areas and the amygdala (22–24).
These neural networks involving cholinergic circuits suggest that
multiple points of regulation can be further explored in studying
the brain control of peripheral inflammation. Some of these
networks have been previously associated with the regulation
of autonomic responses, including modulation of vagus nerve
activity (2). These previous observations are consistent with
our findings that signaling through the vagus nerve mediates
brain cholinergic modulation of peripheral inflammation. Our
findings have clinical relevance. Galantamine is in clinical
use for alleviation of cognitive deterioration in patients with
Alzheimer’s disease. We have also recently shown that treatment
with galantamine alleviates inflammation and insulin resistance
in patients with the metabolic syndrome (45). BQCA and
other centrally-acting positive allosteric modulators of the M1
mAChR have also been preclinically developed in the search of
efficient treatments of Alzheimer’s disease and other neurological
conditions (34, 35). Our results suggest considering these
two types of therapeutics as anti-inflammatory agents. While
optogenetics provide a very selective approach for spatiotemporal
neuronal control in studying neural circuitries (46), this
technology currently has limited therapeutic implications (47–
49). However, medial septum deep brain (electrical) stimulation
has been successfully used for improving spatial workingmemory
and cognition in experimental settings of traumatic brain injury
(50, 51). Future insights into brain networks triggered by medial
septum neuronal stimulation and possibly other regions may
further inform implications of deep brain stimulation and non-
invasive approaches, including transcranial magnetic stimulation
and transcranial direct current stimulation (52–54) in therapeutic
anti-inflammatory strategies.
Basal forebrain cholinergic signaling has a documented role
in attention, learning and memory, and degeneration of basal
forebrain cholinergic neurons, which results in diminished
release of acetylcholine in the forebrain, is one of the hallmarks
of Alzheimer’s disease (23). Intriguingly, increased peripheral
TNF and other pro-inflammatory cytokine levels have been
found in Alzheimer’s disease (55), and peripheral inflammation
has been linked to exacerbation of brain pathogenesis and
neurodegeneration, affecting cholinergic neurons (56, 57). This
may be of importance given that cholinergic neurotransmission
is dysfunctional in different types of dementia (58), suggesting a
potential mechanism by which patients with Alzheimer’s disease
and other types of dementia may be more susceptible to distinct
types of infection (59).
Peripheral inflammation in sepsis, liver disease, and other
inflammatory conditions also is linked with brain inflammation
(2, 60) and deterioration in brain function and delirium
within the scope of characteristic encephalopathies (2, 61–64).
Dysregulation in cholinergic signaling has a documented role in
brain derangements, including delirium and encephalopathies in
sepsis and other inflammatory conditions (60, 65–67). Together
with these previously published findings, our observations
suggest a bidirectional relationship between brain cholinergic
signaling and peripheral inflammation. In this context targeted
pharmacological or device-generated modulation of forebrain
cholinergic signaling may have broader therapeutic implications.
MATERIALS AND METHODS
Animals
Male mice were used in all experiments. BALB/c mice (24–
28 g) were purchased from Taconic. Mice with genetic deletion
of VAChT in the forebrain (VAChT–/– mice) were generated
as previously described (27). Briefly, VAChTflox/flox mouse line
(crossed for five generations with C57BL/6J) was crossed with
the Nkx2.1-Cre mouse line (C57BL/6J-Tg(Nkx2-1-cre)2Sand/J)
(Jackson Laboratory, stock No: 008661). Control VAChT+/+
mice were VAChTflox/flox littermates. ChAT-ChR2-YFP BAC
transgenic mice (Jackson Laboratory, stock No: 014546) (68)
and non-carrier wild type mice (on the C57BL/6 background)
were used in experiments with laser light exposure of the medial
septum neurons. M1 mAChR (Chrm1−/−) KO mice (69) were
generated on the C57Bl/6 background as previously described
(70). M1 mAChR KO and wild type (WT) littermates were
received from Charles River. Animals were allowed to acclimate
for at least 2 weeks prior to the corresponding experiment. All
animals were housed in standard conditions (a 12 h light–dark
cycle) with access to regular chow and water.
Chemicals
Galantamine (Galantamine hydrobromide) (purity ≥95% by
HPLC) was purchased from Calbiochem. Galantamine working
solutions were prepared in sterile saline. Benzyl quinolone
carboxylic acid (BQCA) (purity: ≥97% (HPLC) was purchased
from Enzo Life Sciences. BQCAworking solutions were prepared
in betacyclodextrin and contained 5% betacyclodextrin in sterile
saline (35). Atropine (purity: ≥99% (TLC) and propranolol
(purity: ≥98% (TLC) were purchased from Sigma and working
solutions prepared in sterile saline.
Endotoxemia and Drug Treatment
Endotoxemia in mice was induced by administering LPS
(endotoxin, Sigma L4130 O111:B4 for consistency with our
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previous studies (13, 36, 71, 72) in doses as indicated, injected
i.p.) Groups of animals were treated i.p. with galantamine (3
mg/kg) or different doses of BQCA or vehicle (sterile saline
as a vehicle in galantamine treatments or 5% betacyclodextrin
containing sterile saline as a vehicle in BQCA treatments) 1 h
prior to endotoxin administration. Vehicle or BQCA (5 µg/kg)
[based on the information available about the effect of the
compound on M1 mAChR (34, 35)] was also administered i.c.v.
1 h prior to endotoxin (8 mg/kg, i.p.). In experiments with
optogenetic stimulation LPS was injected i.p. 1 h after the end
of stimulation or sham stimulation. Animals were euthanized
by CO2 asphyxiation 1.5 h after endotoxin administration,
and blood was collected via cardiac puncture (from the right
ventricle) for cytokine (TNF) determination. In other sets of
survival experiments, groups of mice were treated with BQCA
or vehicle (i.p.) 1 h prior to endotoxin (8 mg/kg, i.p.) injection.
Mice were monitored for survival twice daily for the first 5 days,
and then daily for the remainder of the 14 day experiments.
Vagotomy
To avoid potential high lethality associated with bilateral cervical
vagotomy, a unilateral cervical vagotomy was performed. Mice
were anesthetized by isoflurane inhalation and the right cervical
vagus nerve was exposed, ligated with a 4–0 silk suture, and
divided. In sham-operated animals, the cervical vagus nerve was
visualized, but was neither isolated from the surrounding tissues
nor transected. All animals were permitted to recover for 7 days
following the surgical procedure and before their inclusion in
endotoxemia experiments.
Brain Surgical Manipulations and
Optogenetic Stimulation
In experiments with optogenetic stimulation, mice were
anesthetized with isoflurane and placed on a stereotactic frame
(Kopf Instruments). Body temperature was maintained between
36.5 and 37◦C using a feedback controlled rectal thermometer
and heating pad. Using aseptic technique, the scalp was incised
to expose the skull and the overlying connective tissue was
removed. A small (∼500µm) craniotomy was performed on
the desired locations for fiber insertion. Mice expressing light-
activated cation ChR2 tagged with a fluorescent protein (ChR2-
YFP) under the control of the choline acetyltransferase (ChAT)
promoter were used in optogenetic experiments. The optic fiber
was inserted slowly over 3min, targeting the dorsal cholinergic
neurons in the medial septum at a location 0.8mm anterior
to Bregma and 0.7mm lateral to a depth of 3.5mm at a 10
degree angle below dura, which was opened with a 27 gauge
needle. Laser light was delivered via a 200µm diameter fiber
(Thorlabs) inserted into the craniotomy. For ChR2 activation,
a 473 nm laser (Optoengine, LLC) was used at a power of 10
mW at the tip. The laser was controlled by a waveform generator
(Agilent). Stimulation was performed by using square pulses at
20Hz for 10min. Sham stimulation was carried out the same way
with the exception that following optic fiber insertion, no laser
stimulation was performed. Following optogenetic stimulation
or sham stimulation, the fiber was removed over 3min, the
craniotomy was covered using paraffin wax, and the animal
recovered for 1 h on a heating pad at 37◦C prior to LPS injection.
Laser light exposure of medial septum neurons or sham laser
light exposure was performed following the same protocol in
non-carrier mice.
Brain Surgical Manipulations and I.C.V.
Drug Administration
Craniotomies were performed as described above at a location
0.6mm posterior and 1.2mm lateral to Bregma targeting the
right lateral ventricle. A 10 µL Hamilton microsyringe in a
microinjector pump (UMP3-1, World Precision Instruments)
was lowered into the right lateral ventricle over 3min to a depth
of 2.1mm. Following 5min of equilibration, BQCA (5 ug/kg) or
vehicle was delivered over 3min. Following injection, the syringe
remained in place for 5min to prevent backflow. Then the needle
was slowly removed over 3min. The craniotomy was covered
using paraffin wax and the animal recovered for 1 h on a heating
pad at 37◦ C prior to LPS injection.
Immunohistochemistry and
Immunofluorescent Microscopy
Expression of ChR2-EYFP in cholinergic neurons of the
medial septum was confirmed with immunofluorescent staining
for choline acetyltransferase (ChAT) and ChR2-YFP. Mice
underwent intracardiac perfusion with 1 × PBS followed by 4%
paraformaldehyde. Brains were harvested and cryoprotected with
subsequent incubations of 15% and 30% sucrose. They were then
stored in O.C.T. at −20◦C. 20µm sections were collected on
gelatin subbed slides (SouthernBiotech) using a cryostat (Leica
Microsystems). Slides were rinsed in 1 × PBS followed by
washing with 0.25% Triton X-100/1 × PBS (PBT). Blocking was
performed with a solution of 10% MeOH, 0.1% bovine serum
albumin (BSA), 3% normal donkey serum (NDS), and 0.05%
hydrogen peroxide. Slides were then washed in PBT. Cholinergic
neurons were visualized using goat anti-ChAT (Millipore, AB144
1:200, dilution) as a primary antibody and specific ChR2-EYFP
expression was visualized using rabbit anti-GFP Alexa Fluor 488
(ThermoFisher Scientific, A21311, 1:400 dilution) in a solution
of PBT containing 1% NDS. Donkey anti-goat Alexafluor 555
(Thermo Fisher Scientific, A21432, 1:200 dilution) in a solution
of 1% NDS/PBT was used to visualize Goat anti-ChAT, and
slides were mounted and coverslipped with DAPI-Fluoromount
G (Southern BioTech). Images were taken using an Olympus
FluoView FV300 Confocal Laser Scanning Microscope.
In experiments with VAChT−/− and VAChT+/+ animals,
mice were anesthetized with ketamine (100 mg/kg) and xylazine
(25 mg/kg) in 0.9% sodium chloride, and then sacrificed by
trans-cardial perfusion. Brains were harvested and placed in
4% paraformaldehyde in 1 × PBS overnight at 4◦C. The brains
were isolated and 40µm sections of the tissue were obtained
using a vibratome. Brain sections were incubated in a blocking
solution of 1 × PBS/0.4% Triton X-100 containing 0.1% glycine
(wt/vol), 0.1% lysine (wt/vol), 1% BSA (wt/vol), and 1% normal
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donkey serum (wt/vol). Sections were incubated with anti-
VAChT primary antibody (catalog no. 139103; Synaptic Systems)
overnight. Sections were then incubated with the Alexa Fluor 488
anti-rabbit secondary antibody (1:1,000; Life Technologies) for
1 h. The nuclei were labeled with Hoechst. Images were acquired
using the Zeiss LSM 510 Meta confocal system as previously
described (27).
Serum Isolation and
Cytokine Determination
The blood was allowed to clot for 80min following collection.
It was then centrifuged at 5,000 rpm (1,500 × g) for 10min,
and the supernatant (serum) was collected and stored at −20◦C
until analysis. Serum TNF was quantified by using ELISA per the
manufacturer’s instructions (eBioscience).
Electrocardiography (ECG)
Electrocardiograms were recorded using radiotelemeters. The
radio frequency transmitters were implanted subcutaneously
under anesthesia and ECG recordings were initiated following
a minimum recovery period of 7 days post-implantation.
Heart rate was continuously measured in awake, freely moving
mice over 24 h to obtain baseline recordings. To determine
the effect of autonomic blockade, heart rate was recorded
for 60min following administration of atropine (1 mg/kg,
i.p.), propranolol (1 mg/kg, i.p.), or atropine + propranolol.
All data were collected using the Dataquest A.R.T. software
(Transoma Medical). Experiments were performed as previously
described (73, 74).
Statistical Analysis
GraphPad Prism 6.0 software was used for all statistical
analysis. Values are presented as mean ± SEM. One-way
or two-way ANOVA, followed by appropriate post-hoc tests
for multiple comparisons, and a two-tailed two-sample equal
variance Student’s t-test were performed to determine statistical
significance. The statistical significance of differences between
groups of animals in survival experiments was analyzed
by Log-rank test. P values equal to or below 0.05 were
considered significant.
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